Literature DB >> 30150413

BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.

Kao Chin Ngeow1, Hans J Friedrichsen1, Linxin Li1, Zhiqiang Zeng2, Sarah Andrews1, Laurent Volpon3,4, Hannah Brunsdon2, Georgina Berridge1,5, Sarah Picaud6, Roman Fischer5, Richard Lisle1, Stefan Knapp6, Panagis Filippakopoulos6, Helen Knowles7, Eiríkur Steingrímsson8, Katherine L B Borden3,4, E Elizabeth Patton2, Colin R Goding9.   

Abstract

The close integration of the MAPK, PI3K, and WNT signaling pathways underpins much of development and is deregulated in cancer. In principle, combinatorial posttranslational modification of key lineage-specific transcription factors would be an effective means to integrate critical signaling events. Understanding how this might be achieved is central to deciphering the impact of microenvironmental cues in development and disease. The microphthalmia-associated transcription factor MITF plays a crucial role in the development of melanocytes, the retinal pigment epithelium, osteoclasts, and mast cells and acts as a lineage survival oncogene in melanoma. MITF coordinates survival, differentiation, cell-cycle progression, cell migration, metabolism, and lysosome biogenesis. However, how the activity of this key transcription factor is controlled remains poorly understood. Here, we show that GSK3, downstream from both the PI3K and Wnt pathways, and BRAF/MAPK signaling converges to control MITF nuclear export. Phosphorylation of the melanocyte MITF-M isoform in response to BRAF/MAPK signaling primes for phosphorylation by GSK3, a kinase inhibited by both PI3K and Wnt signaling. Dual phosphorylation, but not monophosphorylation, then promotes MITF nuclear export by activating a previously unrecognized hydrophobic export signal. Nonmelanocyte MITF isoforms exhibit poor regulation by MAPK signaling, but instead their export is controlled by mTOR. We uncover here an unanticipated mode of MITF regulation that integrates the output of key developmental and cancer-associated signaling pathways to gate MITF flux through the import-export cycle. The results have significant implications for our understanding of melanoma progression and stem cell renewal.

Entities:  

Keywords:  GSK3; MAPK; MITF; melanoma; nuclear export

Mesh:

Substances:

Year:  2018        PMID: 30150413      PMCID: PMC6140509          DOI: 10.1073/pnas.1810498115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  62 in total

1.  Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.

Authors:  Victoria Marsh Durban; Marian M Deuker; Marcus W Bosenberg; Wayne Phillips; Martin McMahon
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

2.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Authors:  Corine Bertolotto; Fabienne Lesueur; Sandy Giuliano; Thomas Strub; Mahaut de Lichy; Karine Bille; Philippe Dessen; Benoit d'Hayer; Hamida Mohamdi; Audrey Remenieras; Eve Maubec; Arnaud de la Fouchardière; Vincent Molinié; Pierre Vabres; Stéphane Dalle; Nicolas Poulalhon; Tanguy Martin-Denavit; Luc Thomas; Pascale Andry-Benzaquen; Nicolas Dupin; Françoise Boitier; Annick Rossi; Jean-Luc Perrot; Bruno Labeille; Caroline Robert; Bernard Escudier; Olivier Caron; Laurence Brugières; Simon Saule; Betty Gardie; Sophie Gad; Stéphane Richard; Jérôme Couturier; Bin Tean Teh; Paola Ghiorzo; Lorenza Pastorino; Susana Puig; Celia Badenas; Hakan Olsson; Christian Ingvar; Etienne Rouleau; Rosette Lidereau; Philippe Bahadoran; Philippe Vielh; Eve Corda; Hélène Blanché; Diana Zelenika; Pilar Galan; François Aubin; Bertrand Bachollet; Céline Becuwe; Pascaline Berthet; Yves Jean Bignon; Valérie Bonadona; Jean-Louis Bonafe; Marie-Noëlle Bonnet-Dupeyron; Fréderic Cambazard; Jacqueline Chevrant-Breton; Isabelle Coupier; Sophie Dalac; Liliane Demange; Michel d'Incan; Catherine Dugast; Laurence Faivre; Lynda Vincent-Fétita; Marion Gauthier-Villars; Brigitte Gilbert; Florent Grange; Jean-Jacques Grob; Philippe Humbert; Nicolas Janin; Pascal Joly; Delphine Kerob; Christine Lasset; Dominique Leroux; Julien Levang; Jean-Marc Limacher; Cristina Livideanu; Michel Longy; Alain Lortholary; Dominique Stoppa-Lyonnet; Sandrine Mansard; Ludovic Mansuy; Karine Marrou; Christine Matéus; Christine Maugard; Nicolas Meyer; Catherine Nogues; Pierre Souteyrand; Laurence Venat-Bouvet; Hélène Zattara; Valérie Chaudru; Gilbert M Lenoir; Mark Lathrop; Irwin Davidson; Marie-Françoise Avril; Florence Demenais; Robert Ballotti; Brigitte Bressac-de Paillerets
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

3.  Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling.

Authors:  Kim C Mansky; Uma Sankar; Jiahuai Han; Michael C Ostrowski
Journal:  J Biol Chem       Date:  2002-01-15       Impact factor: 5.157

4.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.

Authors:  Suzanne Carreira; Jane Goodall; Laurence Denat; Mercedes Rodriguez; Paolo Nuciforo; Keith S Hoek; Alessandro Testori; Lionel Larue; Colin R Goding
Journal:  Genes Dev       Date:  2006-12-15       Impact factor: 11.361

5.  Mitf-D, a newly identified isoform, expressed in the retinal pigment epithelium and monocyte-lineage cells affected by Mitf mutations.

Authors:  Kazuhisa Takeda; Ken ichi Yasumoto; Naoko Kawaguchi; Tetsuo Udono; Ken ichi Watanabe; Hideo Saito; Kazuhiro Takahashi; Masaki Noda; Shigeki Shibahara
Journal:  Biochim Biophys Acta       Date:  2002-02-20

6.  Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.

Authors:  C Nogueira; K-H Kim; H Sung; K H T Paraiso; J-H Dannenberg; M Bosenberg; L Chin; M Kim
Journal:  Oncogene       Date:  2010-08-16       Impact factor: 9.867

7.  GSK-3-selective inhibitors derived from Tyrian purple indirubins.

Authors:  Laurent Meijer; Alexios-Leandros Skaltsounis; Prokopios Magiatis; Panagiotis Polychronopoulos; Marie Knockaert; Maryse Leost; Xiaozhou P Ryan; Claudia Alin Vonica; Ali Brivanlou; Rana Dajani; Claudia Crovace; Cataldo Tarricone; Andrea Musacchio; S Mark Roe; Laurence Pearl; Paul Greengard
Journal:  Chem Biol       Date:  2003-12

8.  Temperature-sensitive splicing of mitfa by an intron mutation in zebrafish.

Authors:  Zhiqiang Zeng; Stephen L Johnson; James A Lister; E Elizabeth Patton
Journal:  Pigment Cell Melanoma Res       Date:  2014-12-29       Impact factor: 4.693

Review 9.  Beyond BRAF: where next for melanoma therapy?

Authors:  I V Fedorenko; G T Gibney; V K Sondak; K S M Smalley
Journal:  Br J Cancer       Date:  2014-09-02       Impact factor: 7.640

10.  A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo.

Authors:  James A Lister; Amy Capper; Zhiqiang Zeng; Marie E Mathers; Jennifer Richardson; Karthika Paranthaman; Ian J Jackson; E Elizabeth Patton
Journal:  J Invest Dermatol       Date:  2013-07-05       Impact factor: 8.551

View more
  15 in total

1.  Integrative Genomic Analysis Reveals Cancer-Associated Gene Mutations in Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Tyrosine Kinase Inhibitor.

Authors:  Waner Wu; Na Xu; Xuan Zhou; Liang Liu; Yaxian Tan; Jie Luo; Jixian Huang; Jiayue Qin; Juan Wang; Zhimin Li; Changxin Yin; Lingling Zhou; Xiaoli Liu
Journal:  Onco Targets Ther       Date:  2020-08-25       Impact factor: 4.147

Review 2.  Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities.

Authors:  Florian Rambow; Jean-Christophe Marine; Colin R Goding
Journal:  Genes Dev       Date:  2019-10-01       Impact factor: 11.361

Review 3.  MITF-the first 25 years.

Authors:  Colin R Goding; Heinz Arnheiter
Journal:  Genes Dev       Date:  2019-05-23       Impact factor: 11.361

4.  MITF functions as a tumor suppressor in non-small cell lung cancer beyond the canonically oncogenic role.

Authors:  Yi-Jing Hsiao; Wen-Hsin Chang; Hsuan-Yu Chen; Yin-Chen Hsu; Su-Chin Chiu; Ching-Cheng Chiang; Gee-Chen Chang; Yi-Ju Chen; Chia-Yu Wang; Yan-Ming Chen; Chien-Yu Lin; Yu-Ju Chen; Pan-Chyr Yang; Jeremy J W Chen; Sung-Liang Yu
Journal:  Aging (Albany NY)       Date:  2020-12-03       Impact factor: 5.682

5.  Elucidating molecular mechanisms of acquired resistance to BRAF inhibitors in melanoma using a microfluidic device and deep sequencing.

Authors:  Jiyeon Han; Yeonjoo Jung; Yukyung Jun; Sungsu Park; Sanghyuk Lee
Journal:  Genomics Inform       Date:  2021-03-15

6.  MITF activity is regulated by a direct interaction with RAF proteins in melanoma cells.

Authors:  Charlène Estrada; Liliana Mirabal-Ortega; Laurence Méry; Florent Dingli; Laetitia Besse; Cedric Messaoudi; Damarys Loew; Celio Pouponnot; Corine Bertolotto; Alain Eychène; Sabine Druillennec
Journal:  Commun Biol       Date:  2022-01-28

Review 7.  WNT Signaling in Melanoma.

Authors:  Anna Gajos-Michniewicz; Malgorzata Czyz
Journal:  Int J Mol Sci       Date:  2020-07-09       Impact factor: 5.923

8.  3,4,5-Tri-O-Caffeoylquinic Acid Promoted Hair Pigmentation Through β-Catenin and Its Target Genes.

Authors:  Meriem Bejaoui; Myra O Villareal; Hiroko Isoda
Journal:  Front Cell Dev Biol       Date:  2020-03-25

Review 9.  Diverse molecular functions of aspartate β‑hydroxylase in cancer (Review).

Authors:  Wenqian Zheng; Xiaowei Wang; Jinhui Hu; Bingjun Bai; Hongbo Zhu
Journal:  Oncol Rep       Date:  2020-10-06       Impact factor: 3.906

10.  Tuning Transcription Factor Availability through Acetylation-Mediated Genomic Redistribution.

Authors:  Pakavarin Louphrasitthiphol; Robert Siddaway; Alessia Loffreda; Vivian Pogenberg; Hans Friedrichsen; Alexander Schepsky; Zhiqiang Zeng; Min Lu; Thomas Strub; Rasmus Freter; Richard Lisle; Eda Suer; Benjamin Thomas; Benjamin Schuster-Böckler; Panagis Filippakopoulos; Mark Middleton; Xin Lu; E Elizabeth Patton; Irwin Davidson; Jean-Philippe Lambert; Matthias Wilmanns; Eiríkur Steingrímsson; Davide Mazza; Colin R Goding
Journal:  Mol Cell       Date:  2020-06-11       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.